WELCOME TO

ExpreS2ion Biotech

INVESTOR SITE

Upcoming events

Latest press releases

ExpreS2ion announces interim results for the first nine months of 2020

This is a regulatory release

Hørsholm, Denmark, November 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its interim financial results for the first nine months of 2020 and the third quarter of 2020. The Interim Report (Q3) is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion announces successful manufacturing of the cVLP COVID-19 vaccine and further positive updates

This is a regulatory release

Hørsholm, Denmark, November 16, 2020 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus like particle (cVLP) based COVID-19 vaccine, which is licensed to Bavarian Nordic, has been successfully manufactured with a full batch release to follow after final quality analysis. The project remains on track for presenting initial…

Read more

View all